Singular Research Drops Coverage on BioSante Pharma After LibGel Results

In the report, Singular Research writes, "BioSante Pharmaceuticals BPAX LibiGel® performed as expected, but a very strong placebo effectresulted in no statistically significant advantage for LibiGel®.We view this as a display of “mind over matter” fromnurturing women in the trial. Minimally, another clinical trial isnecessary for FDA approval; other new compounds in pipeline areseveral years from approval." BioSante Pharmaceuticals closed today at $0.44, down 7.08% from market open.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsLibGelSingular Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!